Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LDL-C reduction with low- and moderate-intensity statins in type 2 diabetes patients in a community hospital
TCTR20230101001Completed
- Sponsor
- N/A
- Start
- May 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Single-arm trial of ulinastatin in type 2 diabetes mellitus (T2DM) and hypercholesterolemia, sponsored by N/A. Primary endpoint: Change in LDL-C level. Started May 2022; status: completed.
02
Drugs
ulinastatin
03
Conditions
type 2 diabetes mellitus (T2DM)hypercholesterolemia
Beyond the preview
Go deeper on TCTR20230101001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230101001.